by last | Aug 23, 2021 | 2021, Press Releases, Scientific
Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read Moreby mfantozzi | Jul 2, 2021 | 2021, Press Releases, Scientific
Fibromun shows activity in pretreated glioma and sarcoma patients; OncoFAP targets tumor lesions in cancer patients; a new product partnered with AbbVie entered clinical studies Read moreby last | May 13, 2021 | 2021, Press Releases
Philogen will be attending the PEGS Boston Virtual Summit from May 11th to 13th, 2021. Alessandra Villa, Head of Antibody Research will give a lecture with the title “Targeted Immunocytokines” on May 12th. Samuele Cazzamalli, Head of Small Molecule Therapeutics will...by last | May 12, 2021 | 2021, Press Releases, Scientific
COMUNICATO STAMPA 05-12-2021 PRESS RELEASE – 2021-05-12by last | May 6, 2021 | 2021, Press Releases
A virtual briefing will be hosted for sell-side analysts at 10:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021by last | May 4, 2021 | 2021, Press Releases, Scientific
Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer. Philogen announces participation to the 10th World Congress of Melanoma...